Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Allergen‐specific immunotherapy (AIT) is the only available treatment for allergic diseases that can induce specific immune tolerance to allergens. The key mechanisms involved in this process include changes in allergen‐specific regulatory T (Treg) cells.

[1]  M. Steffensen,et al.  A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group , 2018, Allergy.

[2]  D. Barber,et al.  Persistent regulatory T‐cell response 2 years after 3 years of grass tablet SLIT: Links to reduced eosinophil counts, sIgE levels, and clinical benefit , 2018, Allergy.

[3]  C. Bachert,et al.  Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma , 2018, Allergy.

[4]  Y. Okamoto,et al.  Efficacy and safety of SQ house dust mite sublingual immunotherapy‐tablet in Japanese children , 2018, Allergy.

[5]  H. Sampson,et al.  Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut‐sensitized mice , 2018, Allergy.

[6]  M. Akdiş,et al.  Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  S. Kim,et al.  Allergen‐specific immunotherapy induces regulatory T cells in an atopic dermatitis mouse model , 2018, Allergy.

[8]  Y. Okamoto,et al.  Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy , 2018, Allergy.

[9]  H. Lou,et al.  Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: A Meta‐analysis of Randomized Controlled Trials , 2018, Allergy.

[10]  C. Bachert,et al.  Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial , 2018, Allergy.

[11]  K. Bergmann,et al.  New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen‐induced allergic rhinitis , 2018, Allergy.

[12]  O. Pfaar,et al.  Clinical trials in allergen immunotherapy: current concepts and future needs , 2018, Allergy.

[13]  A. Sheikh,et al.  EAACI guidelines on allergen immunotherapy: Executive statement , 2018, Allergy.

[14]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[15]  B. Cases,et al.  Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice , 2018, Allergy.

[16]  C. Akdis,et al.  Microbiome and asthma , 2018, Asthma Research and Practice.

[17]  A. Togias,et al.  Synchronous immune alterations mirror clinical response during allergen immunotherapy , 2017, The Journal of allergy and clinical immunology.

[18]  R. Valenta,et al.  House dust mites as potential carriers for IgE sensitization to bacterial antigens , 2017, Allergy.

[19]  P. Linsley,et al.  A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders , 2017, Science Translational Medicine.

[20]  P Demoly,et al.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper , 2017, Allergy.

[21]  E. d'Hennezel,et al.  Suppression by human FOXP3+ regulatory T cells requires FOXP3-TIP60 interactions , 2017, Science Immunology.

[22]  J. Shelhamer,et al.  Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma. , 2017, The Journal of allergy and clinical immunology.

[23]  K. Ruxrungtham,et al.  High‐dose bee venom exposure induces similar tolerogenic B‐cell responses in allergic patients and healthy beekeepers , 2017, Allergy.

[24]  A. Togias,et al.  Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial , 2017, JAMA.

[25]  S. Durham,et al.  SATB1 is repressed in FoxP3+Tregs following Grass Pollen Subcutaneous and Sublingual Immunotherapy and Correlates with Clinical efficacy , 2017 .

[26]  M. Akdiş,et al.  Role of regulatory B cells in immune tolerance to allergens and beyond. , 2016, The Journal of allergy and clinical immunology.

[27]  W. Lehmacher,et al.  A 12‐week DBPC dose‐finding study with sublingual monomeric allergoid tablets in house dust mite‐allergic patients , 2016, Allergy.

[28]  R. Van Ree,et al.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.

[29]  C. Akdis,et al.  A novel, dual cytokine‐secretion assay for the purification of human Th22 cells that do not co‐produce IL‐17A , 2016, Allergy.

[30]  W. Thomas,et al.  Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization. , 2015, The Journal of allergy and clinical immunology.

[31]  R. Van Ree,et al.  International consensus on allergy immunotherapy. , 2015, The Journal of allergy and clinical immunology.

[32]  E. Elkord,et al.  Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP , 2015, Oncotarget.

[33]  C. Akdis,et al.  T-cell regulation during viral and nonviral asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[34]  M. Kubo,et al.  Helios Enhances Treg Cell Function in Cooperation With FoxP3 , 2015, Arthritis & rheumatology.

[35]  Cezmi A Akdis,et al.  Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens , 2015, The World Allergy Organization journal.

[36]  A. Togias,et al.  Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge , 2015, Allergy.

[37]  C. Akdis,et al.  Advances in allergen immunotherapy: Aiming for complete tolerance to allergens , 2015, Science Translational Medicine.

[38]  H. Schild,et al.  Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo , 2015, Nature Immunology.

[39]  C. Akdis,et al.  Scientific foundations of allergen-specific immunotherapy for allergic disease. , 2014, Chest.

[40]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.

[41]  Stephen J Galli,et al.  Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). , 2014, The Journal of allergy and clinical immunology.

[42]  E. James,et al.  Characterization of CD4+ T cell subsets in allergy. , 2012, Current opinion in immunology.

[43]  E. James,et al.  Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. , 2012, The Journal of allergy and clinical immunology.

[44]  U. Beier,et al.  Helios Expression Is a Marker of T Cell Activation and Proliferation , 2011, PloS one.

[45]  K. Toellner,et al.  Helios Is Associated with CD4 T Cells Differentiating to T Helper 2 and Follicular Helper T Cells In Vivo Independently of Foxp3 Expression , 2011, PloS one.

[46]  E. James,et al.  Direct ex vivo analysis of allergen-specific CD4+ T cells. , 2010, The Journal of allergy and clinical immunology.

[47]  Y. Belkaid,et al.  Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cells , 2010, The Journal of Immunology.

[48]  C. Akdis,et al.  Therapeutic manipulation of immune tolerance in allergic disease , 2009, Nature Reviews Drug Discovery.

[49]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[50]  S. Durham,et al.  Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. , 2008, The Journal of allergy and clinical immunology.

[51]  B. Bohle,et al.  Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. , 2007, The Journal of allergy and clinical immunology.

[52]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[53]  K. Asadullah,et al.  IL-22 increases the innate immunity of tissues. , 2004, Immunity.

[54]  S. Durham,et al.  Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[55]  Marek Jutel,et al.  IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy , 2003, European journal of immunology.

[56]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.